38632-66-5

Upstream product

• 17100-43-5 (4-(but-3-en-1-yl)phenyl)methanol 
• 137658-83-4 4-(3-butenyl)-benzaldehyde 
• 15451-32-8 1-(3-butenyl)-4-bromobenzene 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 123910-88-3 methyl 4-(4-hydroxybut-1-yl)benzoate 

Downstream Products

• 868731-68-4 2-[4-(4-hydroxybutyl)benzylsulfanyl]-3-methylchromen-4-one 

Relevant academic research and scientific papers

Chemo-, regio-, and stereoselective iron-catalysed hydroboration of alkenes and alkynes

The highly chemo-, regio-, and stereoselective synthesis of alkyl- and vinyl boronic esters with good functional group tolerance has been developed using in situ activation of a bench-stable iron(ii) pre-catalyst and pinacolborane (16 examples, 45-95% yield, TOF up to 30000 mol h-1). The first iron-catalysed alkene hydrogermylation is also reported.

Synthesis and biological evaluation of the mitochondrial complex 1 inhibitor 2-[4-(4-fluorobutyl)benzylsulfanyl]-3-methylchromene-4-one as a potential cardiac positron emission tomography tracer

A series of fluorinated chromone analogs with IC50 values ranging from 9 to 133 nM for the mitochondrial complex I (MC-I) has been prepared. A structure-activity relationship (SAR) study of the most potent fluorinated chromone analog 10 demonstrated the linkage heteroatom preference of the side chain region of the molecule while maintaining potent MC-I inhibitory activity. Tissue distribution studies 30 min after [18F]10 administration to Sprague-Dawley (SD) rats demonstrated high uptake of the radiotracer from the blood pool into the myocardium (2.24% ID/g), kidney (1.93% ID/g), and liver (2.00% ID/g). After 2 h about 66% of the activity in the myocardium at 30 min had been retained, whereas ～70% had been cleared from the liver and kidney. MicroPET images of SD rats after [18F]10 administration allowed easy assessment of the myocardium through 60 min with minimal lung or liver interference.

Contrast agents for myocardial perfusion imaging

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.